DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the Respiratory Syncytial Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Respiratory Syncytial Virus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight’s comprehensive report today! @ Respiratory Syncytial Virus Pipeline Outlook

Key Takeaways from Respiratory Syncytial Virus Pipeline Report

• On March 20, 2026- GlaxoSmithKline conducted a phase 3 study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK’s investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.
• On March 17, 2026- Shionogi initiated a phase 2b study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
• On March 05, 2026- Zhuhai Trinomab Pharmaceutical Co., Ltd. conducted a study adopts an adaptive seamless dose selection design and consists of two parts: Part 1 is a phase 2b dose ranging trial which will support to determine the dose for Part 2, the phase 3 trial. The study population includes early and mid-term preterm infants [gestational age (GA)﹤35 weeks 0 day] and late preterm infants or full-term infants (≥35 weeks 0 day GA), with or without Congenital Heart Disease (CHD) or premature infants Chronic Lung Disease (CLD). A total of approximately 2250 infants will be randomized 2:1 to receive either TNM001 or placebo. All subjects will be followed for 240 days after dosing. This study will be conducted in appropriately 50 sites in China.
• DelveInsight’s Respiratory Syncytial Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Respiratory Syncytial Virus treatment.
• The leading Respiratory Syncytial Virus Companies such as AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
• Promising Respiratory Syncytial Virus Pipeline Therapies such as JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Respiratory Syncytial Virus Treatment Drugs

The Respiratory Syncytial Virus Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Respiratory Syncytial Virus Pipeline Report also highlights the unmet needs with respect to the Respiratory Syncytial Virus.

Respiratory Syncytial Virus Overview

RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults. RSV spreads through respiratory droplets and can survive on surfaces for several hours. While most infections are self-limiting, severe cases may require hospitalization, and preventive measures such as good hygiene and vaccination are essential in managing its spread.

Respiratory Syncytial Virus Emerging Drugs Profile

• Clesrovimab: Merck Sharp & Dohme

Clesrovimab (MK-1654) is an investigational extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV-associated medically attended lower respiratory infection (MALRI). Clesrovimab is being studied in infants (pre-term and full-term) to provide rapid, durable protection through their first RSV season with a single, fixed-dose administration. Currently, the drug is in the Phase III stage of its development for the treatment of Respiratory Syncytial Virus (RSV). 

• IVX A12: AstraZeneca

IVX-A12 is a potential bivalent first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses. The FDA has granted IVX-A12 Fast Track designation in adults ≥60 years of age. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate. Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial. The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

• MV-012-968: Meissa Vaccines, Inc

MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from RSV. MV-012-968 is well-tolerated, highly attenuated, and induces a strong systemic and mucosal IgA antibody response in RSV-naïve children. Meissa is currently enrolling participants between the ages of six and 36 months in a Phase Ic clinical study at multiple sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968. MV-012-968 was generated using the company’s proprietary AttenuBlockTM synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

Explore groundbreaking therapies and clinical trials in the Respiratory Syncytial Virus Pipeline @ New Respiratory Syncytial Virus Drugs

The Respiratory Syncytial Virus Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
• Respiratory Syncytial Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market

Respiratory Syncytial Virus Companies

AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.

Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Respiratory Syncytial Virus Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Respiratory Syncytial Virus Market Drivers and Barriers

Scope of the Respiratory Syncytial Virus Pipeline Report

• Coverage- Global
• Respiratory Syncytial Virus Companies- AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
• Respiratory Syncytial Virus Pipeline Therapies- JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
• Respiratory Syncytial Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Respiratory Syncytial Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Respiratory Syncytial Virus Therapies and clinical trials @ Respiratory Syncytial Virus Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Respiratory Syncytial Virus (RSV): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Respiratory Syncytial Virus (RSV) – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Respiratory Syncytial Virus (RSV) Collaboration Deals
9. Late Stage Products (Phase III)
10. Clesrovimab: Merck Sharp & Dohme
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. IVX A12: AstraZeneca
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. MV-012-968: Meissa Vaccines, Inc
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug Name: Company Name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Respiratory Syncytial Virus (RSV) Key Companies
23. Respiratory Syncytial Virus (RSV) Key Products
24. Respiratory Syncytial Virus (RSV)- Unmet Needs
25. Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
26. Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
27. Respiratory Syncytial Virus (RSV) Analyst Views
28. Respiratory Syncytial Virus (RSV) Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight